Iceland· IS-EU/1/17/1178/010-013
XELJANZ
A tofacitinib product containing tofacitinibum inn cítrat, registered in Iceland by Pfizer Europe MA EEIG*. The same ATC class is registered in 13 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Tofacitinib is registered in 13 of 19 countries.
Countries holding a registration under ATC L04AF01 (tofacitinib), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 7 of them publish a price we can compare per daily dose
Tofacitinib · ATC L04AF01
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of tofacitinib costs, country by country.
Normalised to the WHO defined daily dose (10 mg), the median price runs from $1.99 in United States to $17.31 in Switzerland — a ×8.7 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Tofacitinib · price per daily dose (10 mg)
USD · FX 28 Sept 2026
- CH Switzerland$17.31
- US United States$1.99 (acquisition cost)
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Tofacitinibum INN cítrat
- Manufacturer
- Pfizer Europe MA EEIG*
- Country
- Iceland (IS)
- ATC code
- L04AF01
- ATC class
- Tofacitinib
- Defined daily dose
- 10 mg, O
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 1
1 priced- ean09414628 stk x1 þpakkiISK 143125
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
512 interactions on record for tofacitinib.
Graded by severity as the source publishes them — 333 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Tofacitinib · interactions on record
512 records
- 333 severe
- 171 moderate
- 8 minor
Most severe, free to view
- PrednisoloneA07EA01severe
- HydrocortisoneA07EA02severe
- PrednisoneA07EA03severe
- BetamethasoneA07EA04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Tofacitinib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesTofacitinibAjanta Pharma USA Inc.
- CzechiaXELJANZPfizer Europe MA EEIG, Bruxelles
- NorwayXeljanzPfizer Europe MA EEIG (1)
- CanadaTARO-TOFACITINIB XRTARO PHARMACEUTICALS INC
- FinlandXeljanzPfizer Europe MA EEIG
- NetherlandsXeljanz 11 mg, tablet met verlengde afgiftePfizer Europe MA EEIG
- PolandXeljanzPfizer Europe MA EEIG
- SwedenXELJANZ 11 mg DepottablettPfizer Europe MA EEIG
Authorised across Europe · EMA
The same active substance is authorised in 14 EEA countries. Names it is sold under:
- Austria · Tofacitinib Devatis, Tofacitinib Stada
- Bulgaria · Tофацитиниб Devatis
- Denmark · Tofacitinib Accord, Tofacitinib Newbury
- Spain · Tofacitinib Stada
- Finland · Tofacitinib Devatis, Tofacitinib Stada
- France · Tofacitinib Stada
- United Kingdom (Northern Ireland) · Tofacitinib Amarox, Tofacitinib Brown & Burk Uk
- Croatia · Tofacitinib Accord, Tofacitinib Stada
- Liechtenstein · Xeljanz
- Malta · Tofacitinib Stada
- Netherlands · Tofacitinib Devatis, Tofacitinib Stada
- Norway · Tofacitinib Accord, Tofacitinib Devatis
- Portugal · Tofacitinib Bluepharma
- Sweden · Tofacitinib Devatis, Tofacitinib Newbury
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a1aecdb3-901d-4454-8474-730bf3e19dcc GET /v1/drugs/a1aecdb3-901d-4454-8474-730bf3e19dcc?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Forðatafla",
"source": "lyfjastofnun",
"atc_raw": "L04AF01",
"marketed": true,
"strength": "11 mg",
"ma_number": "EU/1/17/1178/010-013",
"substance": "Tofacitinibum INN cítrat",
"other_info": "Ávísun lyfsins er bundin við sérfræðinga í gigtarlækningum, meltingarlækningum og ónæmisfræði.\r\nMarkaðssetning á Íslandi er háð því að Lyfjastofnun hafi staðfest að sérstök skilyrði er varða öryggi og verkun við notkun lyfsins séu uppfyllt.",
"legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
"ma_issued_serial": "43815"
}See everything about tofacitinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.